Emergent BioSolutions: three lost years, and the economy wasn't the reason.
- Industry
- Pharmaceutical Preparations Manufacturing
- Headquarters
- United States
- Ticker
- EBS (NYSE)
- Sources
- SEC filings (2006–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- November 8, 2026
- From profit to three straight losses. Emergent BioSolutions earned $0.6 billion in 2019–2021. Then it lost money every year from 2022 to 2024: $1.2 billion in all. 2025 was its first profit in four years: $0.1 billion.
- It wasn't the cycle. The losses began in 2022, a year the US economy grew 2.4% and factories added jobs. When a company falls while its economy grows, look inside the company first.
- Still smaller than it was. Revenue reached $0.7 billion in 2025, 58% below its 2021 peak of $1.8 billion.
- Leaders came and went. Emergent BioSolutions filed 38 leadership changes since 2016, more than 92% of large manufacturers (the median is 20). The day after each, its shares moved a median 0.3 points against its sector. The news was rarely news.
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $0.5 billion | $0.1 billion | |
| 2017 | $0.6 billion | $0.1 billion | |
| 2018 | $0.8 billion | $0.1 billion | |
| 2019 | $1.1 billion | $0.1 billion | |
| 2020 | $1.6 billion | $0.3 billion | |
| 2021 | $1.8 billion | $0.2 billion | |
| 2022 | $1.1 billion | −$0.2 billion | |
| 2023 | $1 billion | −$0.8 billion | |
| 2024 | $1 billion | −$0.2 billion | |
| 2025 | $0.7 billion | $0.1 billion |
As reported in its annual filings. Losses in red.
Has Emergent BioSolutions had layoffs?
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 1,600 | December 31, 2023 |
| 10-K for 2024 | approximately 900 | December 31, 2024 |
Job cuts, severance and restructuring
Initiated the January 2023 organizational restructuring plan to cut operating costs and improve margins, reducing the workforce by about 125 employees.
“As part of the January 2023 Plan, the Company reduced its workforce by approximately 125 employees.” 10-K for 2023
Initiated the August 2023 restructuring plan to reduce investment in and de-emphasize the Bioservices business, reducing the workforce by about 400 employees.
“As part of the August 2023 Plan, the Company reduced its workforce by approximately 400 employees.” 10-K for 2023
Initiated the May 2024 restructuring plan, cutting the workforce, eliminating vacant positions and closing the Baltimore-Bayview and Rockville facilities.
“These strategic actions led to a reduction of the Company's workforce by approximately 300 employees across all areas of the Company and the elimination of approximately 85 positions that were vacant, as well as the closure of the Company's Baltimore-Bayview Drug Substance manufacturing facility and Rockville, Maryland Drug Product facility.” 10-K for 2024
Initiated the August 2024 restructuring plan at the Lansing facility, reducing the workforce and eliminating several open positions.
“In August 2024, the Company initiated the August 2024 Plan at the Company's Lansing facility, which reduced the Company's workforce by approximately 70 employees, as well as eliminated several open positions.” 10-K for 2024
Sold the Drug Product facility in Baltimore-Camden to Bora Pharmaceuticals Injectables Inc.
“As a result of the divestiture, the Company recognized a loss on sale of business of $36.5 million, net of transaction costs of $3.8 million, during the year ended December 31, 2024.” 10-K for 2024
Reported that employee count declined during 2024 due to the May and August 2024 restructurings and facility sales, and that impacted employees received transition services, severance and benefits.
“During 2024, our number of employees declined by approximately 700 due to the organizational restructurings announced in May and August 2024, the sale of our Hattiesburg facility in July 2024, and the sale of our Camden Manufacturing facility to Bora in August 2024.” 10-K for 2024
| Fiscal year ended | Restructuring charges |
|---|---|
| 2023-12-31 | $29.3 million |
| 2024-12-31 | $22.5 million |
| 2025-12-31 | −$2.1 million |
Emergent BioSolutions filed 4 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
What has Emergent BioSolutions acquired?
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Bavarian Nordic (travel health business)“On May 15, 2023, pursuant to the Purchase and Sale Agreement, we completed the previously announced sale to Bavarian Nordic of our travel health business, including rights to Vaxchora ® and Vivotif ® , as well as our development-stage chikungunya vaccine candidate CHIKV VLP, our manufacturing site in Bern, Switzerland and certain of our development facilities in San Diego, California for a cash purchase price of $270.2 million, subject to certain customary adjustments.” 10-K for 2023 | divestiture | May 15, 2023 | $270.2 million |
Exclusive worldwide rights to brincidofovir from Chimerix Inc.“On September 26, 2022, we acquired exclusive worldwide rights to brincidofovir from Chimerix Inc. for the treatment of any human smallpox disease or any other disease caused by any orthopox virus.” 10-K for 2023 | acquisition | September 26, 2022 | — |
Adapt Pharma Inc.“NARCAN ® Nasal Spray, a product we obtained in connection with our acquisition of Adapt Pharma Inc. in 2018, is an intranasal formulation of naloxone approved by the FDA and Health Canada for the emergency treatment of known or suspected opioid overdose as demonstrated by respiratory and/or central nervous system depression.” 10-K for 2023 | acquisition | 2018 | — |
Bora Pharmaceuticals Injectables Inc. (Drug Product facility in Baltimore-Camden)“At closing, Bora paid a cash purchase price of approximately $35.0 million, which included customary closing adjustments for working capital and transaction expenses of the business.” 10-K for 2024 | divestiture | — | approximately $35.0 million |
SERB (RSDL Reactive Skin Decontamination Lotion)“including RSDL ® (Reactive Skin Decontamination Lotion), which was acquired by SERB on July 31, 2024.” 10-K for 2024 | divestiture | acquired by SERB on July 31, 2024 | — |
travel health business“In 2023, we completed the sale of our Commercial Products Segment's travel health business, including rights to Vivotif ® , the licensed typhoid vaccine; Vaxchora ® , the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company’s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California to Bavarian Nordic.” 10-K for 2025 | divestiture | 2023 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-12-31 | $0 | — | $0 |
| 2017-12-31 | $117.5 million | — | $8,100 |
| 2018-12-31 | $827.7 million | — | $210.6 million |
| 2019-12-31 | $0 | — | $0 |
| 2020-12-31 | $0 | — | $100,000 |
| 2022-12-31 | — | $0 | — |
| 2023-12-31 | — | $270.2 million | — |
| 2024-12-31 | — | $110.2 million | — |
| 2025-12-31 | — | $0 | — |
Deal filings since 2016
- 2026-06-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-04-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-09-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-10-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-09-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-07-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-07-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-05-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-04-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-03-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-05-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-05-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-05-15 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2023-04-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-02-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-09-26 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2022-05-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-10-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-07-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-08-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-07-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-07-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-06-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-09-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-10-15 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2018-10-05 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2018-08-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-08-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-10-06 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-10-03 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-10-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-07-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-07-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-03-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-12-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-09-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-08-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-08-04 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
Who are Emergent BioSolutions's competitors?
Who Emergent BioSolutions names
| Company | Named in |
|---|---|
| Adamis Pharmaceuticals Corporation | 2025 |
| Amneal Pharmaceuticals, Inc. | 2025 |
| Harm Reduction Therapeutics | 2025 |
| KM Biologics | 2025 |
| Padagis LLC | 2025 |
| Summit Biosciences Inc. | 2025 |
| Teleflex Medical Inc. | 2025 |
| ZMI Pharma, Inc. | 2025 |
In its own words
Adamis Pharmaceuticals Corporation, Harm Reduction Therapeutics, Summit Biosciences Inc., Teleflex Medical Inc., ZMI Pharma, Inc.
“NARCAN ® Nasal Spray also faces branded competition from prescription products, such as Zimhi™ (naloxone), a branded injectable product developed by Adamis Pharmaceuticals Corporation, Rextovy TM, (naloxone HCL nasal spray 4 mg), a branded product marketed by ZMI Pharma, Inc., Teleflex Medical Inc.'s Intranasal Mucosal Atomization Device, and Rezenopy ® (naloxone HCL nasal spray 10mg), a branded product manufactured by Summit Biosciences Inc., as well as OTC products, such as RiVive TM (naloxene HCl nasal spray 3mg), a branded product developed by Harm Reduction Therapeutics.” 10-K for 2025
Amneal Pharmaceuticals, Inc., Padagis LLC
“NARCAN ® Nasal Spray also faces generic competition from Padagis LLC (“Padagis”) and Amneal Pharmaceuticals, Inc. (“Amneal”).” 10-K for 2025
KM Biologics
“ACAM2000 ® vaccine also faces competition from KM Biologics LC16m8 vaccine, which is approved in Japan for smallpox and mpox.” 10-K for 2025
Layoffs, acquisitions, competitors and subsidiaries are read from Emergent BioSolutions’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023), as of 2026-02-27.
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 89 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (51 with market data).
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 953 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.
Tools to try
- Ansoff move finderFramework: Ansoff Matrix
- Business model canvas builderFramework: Business Model Canvas
- Change readiness checkFramework: Kotter's 8-Step Change Model
- Five Forces scorerFramework: Porter's Five Forces
- SMART goal builderFramework: SMART Goals
- SWOT builderFramework: SWOT Analysis
More from Stratrix
The Business Model Wizard
Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.
Free · about twelve minutesBuild your Model Thesis →Test a decision, free
Set a live decision against the companies that made it before you.
AcquisitionsThe Distance TestDivestituresThe Divestiture TestDiversificationThe Diversification TestMake or buyThe Make-or-Buy TestStratrix Team
Every Casebook, three Strategy Packs a seat each year and Ask Stratrix, for teams that face these decisions all year.
$1,999 a year · $499 a seatWhat is included →New analyses, by email
The defining moves in business, and what they teach, as they publish.